Breast Cancer Rapid Recommendation Update on Capivasertib-Fulvestrant

On February 6, a rapid recommendation update on Capivasertib-Fulvestrant was published.
The rapid update has implications for two guidelines: Endocrine Treatment and Targeted
Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancers and Biomarkers for
Systemic Therapy in Metastatic Breast Cancer.

© 2021 FLASCO | Premium Website Design by The HDG